Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the data that explains how Context Therapeutics plans to turn its Claudin 6 bispecific antibody, CTIM-76, into a viable cancer therapy often means wading through dense SEC disclosures that can top 200 pages. Investors looking for R&D burn rates, licensing revenue, or the latest trial milestone dates frequently lose hours inside a single footnote. That complexity matters because every financing round and study update can materially shift the outlook for a clinical-stage biotech. Our filings hub tackles that problem head-on.
Type a plain-language question such as “Context Therapeutics SEC filings explained simply� or “How do I read the Context Therapeutics quarterly earnings report 10-Q filing?� and Stock Titan’s AI serves an instant summary. The system also flags “Context Therapeutics insider trading Form 4 transactions� and pushes “Context Therapeutics Form 4 insider transactions real-time� alerts to your dashboard, so you never miss a director buy or a venture fund exit. Need quick context on liquidity? Our AI extracts cash runway metrics from the “Context Therapeutics annual report 10-K simplified� section and highlights any “Context Therapeutics 8-K material events explained,� from clinical holds to secondary offerings. You can even dive into the “Context Therapeutics proxy statement executive compensation� to see how option grants align with trial catalysts, all with one click. That’s “understanding Context Therapeutics SEC documents with AI� in action.
Use these insights to:
- Track “Context Therapeutics earnings report filing analysis� for quarter-over-quarter changes in development spend.
- Monitor “Context Therapeutics executive stock transactions Form 4� before key data readouts.
- Compare pipeline timelines across 10-K, 10-Q, and 8-K disclosures without reading every exhibit.
Every document arrives from EDGAR in real time, then our expert layer converts technical language into clear takeaways you can act on. Complex biotech filings become straightforward investment intelligence.
Context Therapeutics Inc. Schedule 13G/A discloses that Great Point Partners, LLC and two principals, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, report shared beneficial ownership of 4,683,711 shares of Context Therapeutics common stock, representing 5.22% of the outstanding class based on 89,704,194 shares outstanding. The filing states Great Point is investment manager to two record holders (BVF and BOVF) whose holdings are included in the aggregate, while the reporting parties disclaim beneficial ownership except to the extent of pecuniary interests. The report is filed jointly under a dated joint filing agreement and affirms the holdings were not acquired to influence control.
Avidity Partners and affiliated funds filed a Schedule 13G reporting significant passive holdings in Context Therapeutics Inc. The filing discloses that certain Avidity reporting persons hold shared voting and shared dispositive power over 9,126,176 shares, representing approximately 9.9% of the outstanding common stock. Individual fund positions reported in the filing include Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%). Michael Gregory is listed among the reporting persons with the same shared power totaling 9,126,176 shares.
The filing indicates no sole voting or dispositive power for any reporting person and includes a certification that the securities were not acquired to change or influence control of the issuer. Exhibits referenced in the filing include a Joint Filing Agreement and Control Person Identification.
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
